{"product_id":"generic-upadacitinib-upadx","title":"UPADX (Upadacitinib)","description":"\u003cp\u003e\u003cb\u003eUpadacitinib\u003c\/b\u003e is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis.\u003csup id=\"cite_ref-Rinvoq_FDA_label_8-1\" class=\"reference\"\u003e\u003c\/sup\u003eUpadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases.\u003csup id=\"cite_ref-Rinvoq_FDA_label_8-2\" class=\"reference\"\u003e\u003c\/sup\u003e\u003csup id=\"cite_ref-Rinvoq_EPAR_9-2\" class=\"reference\"\u003e\u003c\/sup\u003e These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.\u003csup id=\"cite_ref-Rinvoq_EPAR_9-3\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003cp\u003eCommon side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever.\u003csup id=\"cite_ref-Rinvoq_FDA_label_8-3\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eRheumatoid Arthritis\u003c\/h3\u003e\u003cp\u003eIndicated for moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to ≥1 tumor necrosis factor (TNF) blockers\u003c\/p\u003e\u003cp\u003e15 mg PO qDay\u003c\/p\u003e\u003ch3\u003ePsoriatic Arthritis\u003c\/h3\u003e\u003cp\u003eIndicated for active psoriatic arthritis (PsA) in adults who have had an inadequate response or intolerance to ≥1 TNF blockers\u003c\/p\u003e\u003cp\u003e15 mg PO qDay\u003c\/p\u003e\u003ch3\u003eAtopic Dermatitis\u003c\/h3\u003e\u003cp\u003eIndicated for refractory moderate-to-severe atopic dermatitis (AD) in adults whose disease is not adequately controlled with other systemic therapies or if those therapies are inadvisable\u003c\/p\u003e\u003ch4\u003e\u0026lt;65 years\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e15 mg PO qDay initially; consider increasing to 30 mg qDay if an adequate response is not achieved\u003c\/li\u003e\n\u003cli\u003eDiscontinue if 30-mg dose if adequate response not achieved\u003c\/li\u003e\n\u003cli\u003eUse lowest effective dose needed to maintain response\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eUlcerative Colitis\u003c\/h3\u003e\u003cp\u003eIndicated for moderate to severe active ulcerative colitis (UC) in adults who had inadequate response or intolerance to ≥1 TNF blocker\u003c\/p\u003e\u003cp\u003eInduction: 45 mg PO qDay x 8 weeks\u003c\/p\u003e\u003ch4\u003eMaintenance\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e15 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eRefractory, severe, or extensive disease: Consider 30 mg qDay\u003c\/li\u003e\n\u003cli\u003eUse lowest effective dosage needed to maintain response\u003c\/li\u003e\n\u003cli\u003eDiscontinue if unable to achieve adequate therapeutic response with 30 mg\/day\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eAnkylosing Spondylitis\u003c\/h3\u003e\u003cp\u003eIndicated for active ankylosing spondylitis (AS) in adults who have had an inadequate response or intolerance to ≥1 TNF blockers\u003c\/p\u003e\u003cp\u003e15 mg PO qDay\u003c\/p\u003e\u003ch3\u003eNonradiographic Axial Spondyloarthritis\u003c\/h3\u003e\u003cp\u003eIndicated for active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy\u003c\/p\u003e\u003cp\u003e15 mg PO qDay\u003c\/p\u003e\u003ch3\u003eCrohn Disease\u003c\/h3\u003e\u003cp\u003eIndicated for moderately-to-severely active Crohn disease in adults who have had an inadequate response or intolerance to ≥1 TNF blockers\u003c\/p\u003e\u003cp\u003eInduction: 45 mg PO qDay x 12 weeks\u003c\/p\u003e\u003cp\u003eMaintenance: 15 mg PO qDay; consider 30 mg qDay for patients with refractory, severe, or extensive disease\u003c\/p\u003e\u003cp\u003eDiscontinue if unable to achieve an adequate therapeutic response with 30-mg dosage\u003c\/p\u003e\u003cp\u003eUse lowest effective dose needed to maintain response\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eCoadministration of strong CYP3A4 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eRA, PsA, AD, AS, or nr-axSpA: 15 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUC: 30 mg qDay x 8 weeks for induction, then 15 mg qDay for maintenance\u003c\/li\u003e\n\u003cli\u003eCD: 30 mg qDay x 12 weeks for induction, then 15 mg qDay for maintenance\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eInfection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eIf serious infection (eg, serious opportunistic infections) develops, interrupt treatment until infection is controlled\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eDose interruption for laboratory abnormalities\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAbsolute neutrophil count (ANC) \u0026lt;1000 cells\/mm\u003csup\u003e3\u003c\/sup\u003e: Interrupt; may restart once ANC \u0026gt;1000 cells\/mm\u003csup\u003e3\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eAbsolute lymphocyte count (ALC) \u0026lt;500 cells\/mm\u003csup\u003e3\u003c\/sup\u003e: Interrupt; may restart once ALC \u0026gt;500 cells\/mm\u003csup\u003e3\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eHemoglobin (Hb) \u0026lt;8 g\/dL: Interrupt; may restart once Hb \u0026gt;8 g\/dL\u003c\/li\u003e\n\u003cli\u003eHepatic transaminases: Interrupt if drug-induced liver injury suspected\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eRA, PsA, AS, or nr-axSpA\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild (eGFR 60 to \u0026lt; 90 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e), moderate (eGFR 30 to \u0026lt; 60 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e), severe renal impairment (eGFR 15 to \u0026lt; 30 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No dose adjustment necessary\u003c\/li\u003e\n\u003cli\u003eESRD: Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eAD\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild or moderate (eGFR \u0026gt;30 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No dose adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR \u0026lt;30 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): 15 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eESRD: Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eUC\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild or moderate (eGFR \u0026gt;30 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No dose adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR 15 to \u0026lt;30 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): 30 mg qDay x 8 weeks for induction, then 15 mg qDay for maintenance\u003c\/li\u003e\n\u003cli\u003eESRD (eGFR \u0026lt;15 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eCrohn disease\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild-to-moderate (eGFR ≥30 mL\/min\/1.73m\u003csup\u003e2\u003c\/sup\u003e): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR 15 to \u0026lt;30 mL\/min\/1.73m\u003csup\u003e2\u003c\/sup\u003e): 30 mg qDay for 12 weeks for induction; 15 mg qDay for maintenance\u003c\/li\u003e\n\u003cli\u003eESRD (eGFR ≥30 mL\/min\/1.73m\u003csup\u003e2\u003c\/sup\u003e): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eRA, PsA, AS, nr-axSpA, or AD\u003c\/p\u003e\n\u003cul\u003e\u003cli\u003eMild or moderate (Child-Pugh A or B): No dose adjustment required\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eRA, PsA, AS, nr-axSpA, UC, CD, or AD\u003c\/p\u003e\n\u003cul\u003e\u003cli\u003e\u003cp\u003eSevere (Child-Pugh C): Not recommended\u003c\/p\u003e\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eUC\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh A or B): 30 mg qDay x 8 weeks for induction, then 15 mg qDay for maintenance\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eCrohn disease\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh A or B): 30 mg qDay for 12 weeks for induction; 15 mg qDay for maintenance\u003c\/li\u003e\n\u003cli\u003eSevere (Child Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eALC \u0026lt;500 cells\/mm\u003csup\u003e3\u003c\/sup\u003e, ANC \u0026lt;1000 cell\/mm\u003csup\u003e3\u003c\/sup\u003e, or Hb \u0026lt;8 g\/dL: Do not initiate\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch4\u003eBefore initiating\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eTest for tuberculosis (TB) before initiating; initiate antitubercular treatment for previously untreated latent TB or active TB before initiating treatment\u003c\/li\u003e\n\u003cli\u003eVerify pregnancy status in females of reproductive potential before initiating\u003c\/li\u003e\n\u003cli\u003eScreen viral hepatitis in accordance with clinical guidelines\u003c\/li\u003e\n\u003cli\u003eUpdate immunizations according to current immunization guidelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch4\u003eLimitations of use\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eRA, PsA, AS or nr-axSpA: Use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants (eg, azathioprine, cyclosporine), is not recommended\u003c\/li\u003e\n\u003cli\u003eAD: Not recommended in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants\u003c\/li\u003e\n\u003cli\u003eUC, CD: Not recommended in combination with other JAK inhibitors, biological therapies, or potent immunosuppressants (eg, azathioprine, cyclosporine)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797950165035,"sku":"RL1520230918100","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-09-1768.jpg?v=1787022146","url":"https:\/\/xomeds.com\/products\/generic-upadacitinib-upadx","provider":"XOMEDS","version":"1.0","type":"link"}